TSG101 protein steady-state level is regulated posttranslationally by an evolutionarily conserved COOH-terminal sequence

Cancer Research

Volumn 60, Issue 6, 2000, Pages 1736-1741

  Feng, Guo Hong ^a,b   Lih, Chih Jian ^b   Cohen, Stanley N ^b  

^a Cereon Genomics   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; GENE CONTROL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TRANSLATION REGULATION;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CONSERVED SEQUENCE; DNA-BINDING PROTEINS; DOWN-REGULATION; EVOLUTION, MOLECULAR; GENE EXPRESSION REGULATION; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; TRANSCRIPTION FACTORS;

EID: 0001615861     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Li, L., and Cohen, S. N. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell, 85: 319-329, 1996.
2. Xie, W., Li, L., and Cohen, S. N. Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. Proc. Natl. Acad. Sci. USA, 95: 1595-1600, 1998.
3. Li, L., Li, X., Francke, L., and Cohen, S. N. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell, 88: 143-154, 1997.
4. Li, L., Francke, U., and Cohen, S. N. Retraction. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell. 93: 660, 1998.
5. Steiner, P., Barnes, D. M., Harris, W. H., and Weinberg, R. A. Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer. Nat. Genet., 16: 332-333, 1997.
6. Gayther, S. A., Barski, P., Batley, S. J., Li, L., de Foy, K. A., Cohen, S. N., Ponder, B. A., and Caldas, C. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene. 15: 2119-2126, 1997.
7. Lee, M. P., and Feinberg, A. P. Aberrant splicing but not mutations of TSG101 in human breast cancer. Cancer Res., 57: 3131-3134, 1997.
8. Wang, Q., Driouch, K., Courtois, S., Champeme, M. H., Bieche, I., Treilleux, I., Briffod, M., Rimokh, R., Magaud, J. P., Curmi, P., Lidereau, R., and Puisieux, A. Low frequency of TSG101/CC2 gene alterations in invasive human breast cancers. Oncogene, 16: 677-679, 1998.
9. Wagner, K. U., Dierisseau, P., Rucker, E. B., III, Robinson, G. W., and Hennighausen, L. Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants. Oncogene, 17: 2761-2770, 1998.
10. Carney, M. E., Maxwell, G. L., Lancaster, J. M., Gumbs, C., Marks, J., Berchuck, A., and Futreal, P. A. Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers. J. Soc. Gynecol. Investig. 5: 281-285, 1998.
11. Lin, S. Y., Chen, Y. J., and Chang, J. G. Multiple truncated transcripts of TSG101 in gastrointestinal cancers. J. Gastroenterol. Hepatol., 13: 1111-1114, 1998.
12. Oh, Y., Proctor, M. L., Fan, Y. H., Su, L. K., Hong, W. K., Fong, K. M., Sekido, Y. S., Gazdar, A. F., Minna, J. D., and Mao, L. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer. Oncogene, 17: 1141-1148, 1998.
13. Sun, Z., Pan. J., Buhley, G., and Balk, S. P. Frequent abnormalities of TSG101 transcripts in human prostate cancer. Oncogene. 15: 3121-3125, 1997.
14. Ponting, C. P., Cai, Y.D., and Bork, P. The breast cancer gene product TSG101: a regulator of ubiquitination? J. Mol. Med., 75: 467-469, 1997.
15. Koonin, E. V., and Ahagyan, R. A. TSG101 may be the prototype of a class of dominant negative ubiquitin regulators. Nat. Genet., 16: 330-331, 1997.
16. Watanabe, M., Yanagi, Y., Masuhiro, Y., Yano, T., Yoshikawa, H., Yanagisawa, J., and Kato, S. A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain. Biochem. Biophys. Res. Commun., 245: 900-905, 1998.
17. Sun, Z., Pan, J., Hope, W. X., Cohen, S. N., and Balk, S. P. Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300. Cancer (Phila.), 86: 689-696, 1999,
18. Hittelman, A. B., Burakov, D., Iñiguez-Lluhí, J. A., Freedman, L. P., and Garabedian, M. J. Differential regulation of glucocorticoid receptor transcriptional activation. EMBO J., in press, 2000.
19. Zhong, Q., Chen, Y., Jones, D., and Lee, W. H. Perturbation of TSG101 protein affects cell cycle progression. Cancer Res., 58: 2699-2702, 1998.
20. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, Ed. 2. Plainview, NY: Cold Spring Harbor Laboratory, 1989.
21. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. Mdm2 promotes the rapid degradation of p53. Nature (Lond.), 387: 296-299, 1997.
22. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. Regulation of p53 stability by Mdm2. Nature (Lond.), 387: 299-303, 1997.
23. Kubbutat, M. H., Ludwig, R. L., Ashcroft, M., and Vousden, K. H. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol. Cell. Biol., 18: 5690-5698, 1998.
24. Zhong, Q., Chen, C. F., Chen, Y., Chen, P. L., and Lee, W. H. Identification of cellular TSG101 protein in multiple human breast cancer cell lines. Cancer Res., 57: 4225-4228, 1997.
25. Devereux, J., Haeberli, P., and Smithies, O. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res., 12: 387-395, 1984.